# Conversion Therapy With Sintilimab Plus CAPOX in Patients With Unresectable Locally Advanced or Limited Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction

> **NCT04263870** · PHASE2 · UNKNOWN · sponsor: **Sichuan University** · enrollment: 36 (estimated)

## Conditions studied

- Gastroesophageal Junction Adenocarcinoma
- Stomach Adenocarcinoma
- Locally Advanced Unresectable Gastric Adenocarcinoma
- Metastatic Gastric Cancer

## Interventions

- **DRUG:** sintilimab

## Key facts

- **NCT ID:** NCT04263870
- **Lead sponsor:** Sichuan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-03
- **Primary completion:** 2021-05
- **Final completion:** 2021-10
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2020-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04263870

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04263870, "Conversion Therapy With Sintilimab Plus CAPOX in Patients With Unresectable Locally Advanced or Limited Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04263870. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*